Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening?

The Lancet Oncology

Volumn 10, Issue 9, 2009, Pages 920-925

  Achatz, Maria Isabel Waddington ^a   Hainaut, Pierre ^b   Ashton Prolla, Patricia ^c  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; HISTIDINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADRENAL CANCER; AUTOSOMAL DOMINANT DISORDER; BRAZIL; CANCER DIAGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHILDHOOD CANCER; CODON; COMPUTER ASSISTED TOMOGRAPHY; FALSE POSITIVE RESULT; FAMILIAL CANCER; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; HEALTH CARE COST; HEALTH PROGRAM; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ETHICS; MUTATIONAL ANALYSIS; NEWBORN SCREENING; PEDIGREE ANALYSIS; PENETRANCE; POPULATION GENETICS; POPULATION STRUCTURE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RADIODIAGNOSIS; REVIEW; RISK MANAGEMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BRAZIL; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; NEOPLASMS; PREVALENCE;

EID: 69249164841     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70089-0     Document Type: Review

References (43)

1. Borry P., Stultiens L., Nys H., Cassiman J.-J., and Dierickx K. Presymptomatic and predictive genetic testing in minors: a systematic review of guidelines and position papers. Clin Genet 70 (2006) 374-381
2. Forrest L.E., Delatycki M.B., Skene L., and Aitken M.A. Communicating genetic information in families-a review of guidelines and position papers. Eur J Hum Genet 15 (2007) 612-618
3. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21 (2003) 1-10
4. Public and Professional Policy Committee (PPPC) of the European Society of Human Genetics (2007-2008). Genetic testing in asymptomatic minors. http://www.eurogentest.org/professionals/public_health/info/public/unit3 /final_recommendations_genetic_counselling.xhtml#a_N1058F (accessed March 10, 2009).
5. Bioethics Committee, Canadian Paediatric Society (CPS) and Ethics and Public Policy Committee, Canadian College of Medical Geneticists. Guidelines for genetic testing of healthy children. A joint statement with the Canadian College of Medical Geneticists. Paediatr Child Health 8 (2003) 42-45
6. Online Mendelian Inheritance in Man (OMIM). Li-Fraumeni syndrome. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=151623 (accessed March 10, 2009).
7. Li F.P., Fraumeni Jr. J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 48 (1988) 5358-5362
8. Malkin D., Li F.P., Strong L.C., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250 (1990) 1233-1238
9. Birch J.M., Alston R.D., McNally R.J., et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20 (2001) 4621-4628
10. Olivier M., Goldgar D.E., Sodha N., et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 63 (2003) 6643-6650
11. Lalloo F., Varley J., Ellis D., et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 361 (2003) 1101-1102
12. Achatz M.I., Olivier M., Le Calvez F., et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245 (2007) 96-102
13. Palmero E.I., Schüler-Faccini L., Caleffi M., et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 261 (2008) 21-25
14. Piovesan GC. Prevalence of the R337H TP53 allele in the State of Paraná. Thesis, Federal University of Paraná, Brazil, 2006 (in Portuguese).
15. Ribeiro R.C., Sandrini F., Figueiredo B., et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98 (2001) 9330-9335
16. Figueiredo B.C., Sandrini R., Zambetti G.P., et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43 (2006) 91-96
17. Assumpção J.G., Seidinger A.L., Mastellaro M.J., et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 8 (2008) 357
18. Nelson H.D., Huffman L.H., Fu R., Harris E.L., and US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 143 (2005) 362-379
19. The UK collaborative study of newborn screening for medium chain acyl co-A dehydrogenase deficiency (UKCSNS-MCADD). http://www.newbornbloodspot.screening.nhs.uk/mcadd/downloads/WebsiteSumm ary_MCADDstudy.doc (accessed July 28, 2009).
20. Wilson J.M., and Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65 (1968) 281-393
21. Andermann A., Blancquaert I., Beauchamp S., and Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86 (2008) 317-319
22. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., and Arva N.C. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119 (2004) 591-602
23. Bougeard G., Baert-Desurmont S., Tournier I., et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43 (2006) 531-533
24. Burt E.C., McGown G., Thorncroft M., James L.A., Birch J.M., and Varley J.M. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer 80 (1999) 9-10
25. Thull D.L., and Vogel V.G. Recognition and management of hereditary breast cancer syndromes. Oncologist 9 (2004) 13-24
26. Wong P., Verselis S.J., Garber J.E., et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 130 (2006) 73-79
27. Masciari S., Van den Abbeele A.D., Diller L.R., et al. F18-fluorodeoxyglucosepositron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299 (2008) 1315-1319
28. Icard P., Goudet P., Charpenay C., et al. Adrenocortical carcinomas: surgical trends and results in 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25 (2001) 891
29. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Guidelines for detection, prevention, and risk reduction. Genetic/familial high-risk assessment: breast and ovarian; Li-Fraumeni Syndrome. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed March 10, 2009).
30. AAP Newborn Screening Task Force. Newborn screening: a blueprint for the future executive summary: newborn screening taskforce report. Pediatrics 106 (2000) 389-427
31. Atkinson K., Zuckerman B., Sharfstein J.M., Levin D., Blatt R.J., and Koh H.K. A public health response to emerging technology: expansion of the Massachussets newborn screening program. Public Health Rep 116 (2001) 122-131
32. American Thoracic Society/European Respiratory Society. AmericanThoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 168 (2003) 818-900
33. Grosse S.D., Boyle C.A., Botkin J.R., et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53 (2004) 1-36
34. Woods W.G., Gao R.N., Shuster J.J., et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 346 (2002) 1041-1046
35. Soderstrom L., Woods W.G., Bernstein M., Robison L.L., Tuchman M., and Lemieux B. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening. J Natl Cancer Inst 97 (2005) 1118-1124
36. Li F.P., Garber J.E., Friend S.H., et al. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 84 (1992) 1156-1160
37. Frebourg T., Abel A., Bonaiti-Pellie C., et al. Li-Fraumeni syndrome: update, new data and guidelines for clinical management. Bull Cancer 88 (2001) 581-587
38. Malkin D. Predictive genetic testing for childhood cancer: taking the road less traveled by. J Pediatr Hematol Oncol 26 (2004) 546-549
39. Prochazkova K., Prochazkova K., Foretova L., and Sedlacek Z. A rare tumor and an ethical dilemma in a family with a germline TP53 mutation. Cancer Genet Cytogenet 180 (2008) 65-69
40. Duncan R.E., Gillam L., Savulescu J., Williamson R., Rogers J.G., and Delatycki M.B. "You're one of us now": young people describe their experiences of predictive genetic testing for Huntington Disease (HD) and familial adenomatous polyposis (FAP). Am J Med Genet C 148C (2008) 47-55
41. McConkie-Rosell A., Spiridigliozzi G.A., Melvin E., Dawson D.V., and Lachiewicz A.M. Living with genetic risk: effect on adolescent self concept. Am J Med Genet C 148C (2008) 56-69
42. Otlowski M. An exploration of the legal and socio-ethical implications of predictive genetic testing of children. Aust J Fam Law 18 (2004) 147-169
43. Offit K., and Thom P. Ethical and legal aspects of cancer genetic testing. Semin Oncol 34 (2007) 435-443